Scarica l'app Stockscreener
1.66
0.00%
0.00
Dopo l'orario di chiusura:
1.66
Precedente Chiudi:
$1.66
Aprire:
$1.67
Volume 24 ore:
2.11M
Relative Volume:
0.52
Capitalizzazione di mercato:
$440.51M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-5.9286
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
+7.79%
1M Prestazione:
-10.27%
6M Prestazione:
-54.52%
1 anno Prestazione:
-8.79%
Intervallo 1D:
$1.65
$1.70
Intervallo di 1 settimana:
$1.53
$1.70
Portata 52W:
$1.445
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.66 | 440.51M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - moha.gov.vn
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN
Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
With Akebia Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Why Akebia Therapeutics Inc. (AX9) stock could be top winnerQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN
HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Buy Recommendation - MSN
BTIG Reiterates Buy Rating for Akebia Therapeutics (AKBA) | AKBA Stock News - GuruFocus
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance
Akebia Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating for AKBA, Price Target Unchanged | AKBA Stock News - GuruFocus
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Is Akebia Therapeutics Inc a good long term investmentStock Market Trends & Access Free Tools and Start Investing - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock sustain revenue momentumEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Is Akebia Therapeutics Inc. (AX9) stock protected from inflationTrade Volume Report & Free Technical Confirmation Trade Alerts - Newser
Cyclerion Receives Milestone Payment from Akebia - TipRanks
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics (Nasdaq: AKBA) announces 22,576-share inducement grant - Stock Titan
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 sells rare kidney disease drug to Akebia for $12M up front - BioWorld MedTech
Q32 Bio skyrockets as it sells complement inhibitor ADX-097 - The Pharma Letter
Akebia Therapeutics, Inc. Announces Establishment of Rare Kidney Disease Pipeline - marketscreener.com
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - Benzinga
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - marketscreener.com
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Akebia announces establishment of rare kidney disease pipeline - marketscreener.com
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Akebia Therapeutics (AKBA) Expands Pipeline with Rare Kidney Dis - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Inhibitor ADX-097 - GuruFocus
Q32 Bio sells complement inhibitor ADX-097 to Akebia - TipRanks
Akebia Therapeutics Acquires Global Rights to ADX-097 - TipRanks
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline with Acquisition of AKB-097 and Initiation of Praliciguat Phase 2 Trial - Quiver Quantitative
Geode Capital Management LLC Acquires 1,043,718 Shares of Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Is Akebia Therapeutics Inc. stock a buy on dips2025 Volume Leaders & Free Safe Capital Growth Stock Tips - BỘ NỘI VỤ
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Why analysts recommend Akebia Therapeutics Inc. (AX9) stockQuarterly Portfolio Review & Weekly Momentum Stock Picks - BỘ NỘI VỤ
Why Akebia Therapeutics Inc. stock is a must watch in 2025Quarterly Growth Report & Real-Time Volume Spike Alerts - moha.gov.vn
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.48%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):